Naslov
CD95 expression on peripheral blood T lymphocytes in patients with relapsing-remitting, primary and secondary progressive multiple sclerosis

Autori
Petelin, Željka ; Brinar, Vesna V. ; Petravić, Damir ; Zurak, Niko ; Golemović, Mirna ; Batinić, Drago ; Ivanković, Davor

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 3rd Dubrovnik International Conference on Multiple Sclerosis and Continuing Education ; u: Neurologia Croatica. Supplement (ISSN 1331-5196) 54 (2005) (S1) / - , 2005, 45-46

Skup
Dubrovnik International Conference on Multiple Sclerosis and Continuing Education (3 ; 2005)

Mjesto i datum
Dubrovnik, Hrvatska, 18.05.2005. - 21.05.2005

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
multiple sclerosis; apoptosis; CD95/Fas; T lymphocytes; Flow cytometric-immunophenotyping

Sažetak
CD95-mediated apoptosis is a potent endogenous pathway of T lymphocyte elimination that has been suggested to be altered in multiple sclerosis (MS). The aim of this study was to analyse the expression of CD95 molecule on peripheral blood CD4+ and CD8+ T lymphocytes in patients with relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS). The analysis was done immediately before and after pulse corticosteroid therapy (consisting of intravenous methylprednisolone 1000 mg/day in 250 ml physiological saline in short infusions during five days), and six months after the beginning of investigation, when RRMS patients were in the remission. The prospective study included 50 patients with multiple sclerosis diagnosed by McDonald&#8217; s criteria: 27 patients with RRMS (4M, 23 F) in the age from 20 to 51 years with median of 37 years, 10 patients with PPMS (5M, 5F) in the age from 24 to 57 years with median of 39.5 years, and 13 patients with SPMS (4M, 9F) in the age from 30 to 53 years with median of 42 years. Disease duration in the group of RRMS patients was from 3 months to 17 years with median of 2 years, in the group of PPMS patients from 1.5 to 14 years with median of 4 years, and in the group of SPMS patients from 3 to 26 years with median of 11 years. Average EDSS scale in the group of RRMS patients was 3.24 +/- 1.18, in the group of PPMS patients 5 +/- 1.55, and in the group of SPMS patients 5.62 +/- 1.24. The proportions of CD95+ T lymphocyte subsets were analysed by the use of monoclonal antibodies (anti-CD4-PE/Cy5, anti-CD8-FITC and anti-CD95-PE, DAKO) and flow cytometry (FACSscan cytometer and CellQuest software, Becton Dickinson). The results were presented by means +/- SD. For statistical analysis Two-way ANOVA for repeated-measures with post hoc Sheffe&#8217; s test was used. The p values < 0.05 were considered as statistically significant. The proportion of CD4+CD95+ T lymphocytes significantly decreased after therapy in RRMS patients (46.91 +/- 7.79 vs. 39.5 +/- 5.67, p< 0.01), PPMS patients (46.16 +/- 5.9 vs. 40.02 +/- 7.22, p< 0.01) and SPMS patients (51.26 +/- 6.56 vs. 44.68 +/- 7.75, p< 0.01). After six months the same proportion significantly increased in PPMS patients (40.02 +/- 7.22 vs. 46.1 +/- 5.95, p< 0.01) and SPMS patients (44.68 +/- 7.75 vs. 50.99 +/- 6.46, p< 0.01), while in RRMS patients the same proportion further significantly decreased (39.5 +/- 5.67 vs. 36.1 +/- 4.62, p< 0.01). The proportion of CD8+CD95+ T lymphocytes also decreased in all three group of patients after therapy, although significantly only in RRMS patients (26.71 +/- 5.21 vs. 18.89 +/- 5.05, p< 0.01) and SPMS patients (21.25 +/- 4.35 vs. 17.17 +/- 5.83, p< 0.05). After six months the same proportion increased in patients with progressive form of the disease, significantly only in SPMS patients (17.17 +/- 5.83 vs. 21.21 +/- 4.59, p< 0.05) and, although not significantly, decreased in RRMS patients. Conclusions: The differences in dynamics of stated laboratory parameters, indicators of T lymphocyte apoptosis, point to the different patophysiologic events in RRMS patients compared to the PPMS and SPMS patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA